Finch Therapeutics Group Inc
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in hu… Read more
Market Cap & Net Worth: Finch Therapeutics Group Inc (FNCH)
Finch Therapeutics Group Inc (PINK:FNCH) has a market capitalization of $21.68 Million ($21.68 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #25244 globally and #8637 in its home market, demonstrating a -3.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Finch Therapeutics Group Inc's stock price $13.50 by its total outstanding shares 1605763 (1.61 Million).
Finch Therapeutics Group Inc Market Cap History: 2021 to 2025
Finch Therapeutics Group Inc's market capitalization history from 2021 to 2025. Data shows change from $480.28 Million to $21.68 Million (-61.46% CAGR).
Finch Therapeutics Group Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Finch Therapeutics Group Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
54.18x
Finch Therapeutics Group Inc's market cap is 54.18 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $480.28 Million | $18.53 Million | -$55.86 Million | 25.92x | N/A |
| 2022 | $23.12 Million | $861.00K | -$114.65 Million | 26.86x | N/A |
| 2023 | $5.80 Million | $107.00K | -$74.75 Million | 54.18x | N/A |
Competitor Companies of FNCH by Market Capitalization
Companies near Finch Therapeutics Group Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Finch Therapeutics Group Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Finch Therapeutics Group Inc Historical Marketcap From 2021 to 2025
Between 2021 and today, Finch Therapeutics Group Inc's market cap moved from $480.28 Million to $ 21.68 Million, with a yearly change of -61.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $21.68 Million | +12.50% |
| 2024 | $19.27 Million | +232.41% |
| 2023 | $5.80 Million | -74.93% |
| 2022 | $23.12 Million | -95.19% |
| 2021 | $480.28 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Finch Therapeutics Group Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.68 Million USD |
| MoneyControl | $21.68 Million USD |
| MarketWatch | $21.68 Million USD |
| marketcap.company | $21.68 Million USD |
| Reuters | $21.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.